Corneal Staining Associated With Daily Disposable Beauty Contact Lenses

Overview

Limbal ring contact lenses enhance the look of the eye by adding pigmentation in a ring pattern to the contact lens. The purpose of this investigation is to determine if corneal staining increase is dependent upon the lens pigment location.

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Primary Purpose: Basic Science
  • Masking: Single (Participant)
• Study Primary Completion Date: August 2013

Interventions

• Device: etafilcon A
  • Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
• Device: 2-HEMA, EGDMA Non-ionic
  • Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
• Device: hefilcon A
  • Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.

Arms, Groups and Cohorts

• Other: etafilcon A/2-HEMA, EGDMA/hefilcon A
  • Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
• Other: etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic
  • Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
• Other: 2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A
  • Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
• Other: 2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A
  • Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
• Other: hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A
  • Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
• Other: hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic
  • Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.

Clinical Trial Outcome Measures

Primary Measures

• Corneal Staining
  • Time Frame: 20 minutes and 7 hours post lens fitting
  • Corneal staining was evaluated in 5 corneal regions (Central, Inferior, Nasal, Temporal and Superior) using Sodium Fluorescein strips. The corneal Staining was graded using the scale Grade 0: No Staining, Grade 1: Trace(Minimal superficial staining or stippling), Grade 2: Mild (Regional or diffuse punctate staining), Grade 3:Moderate(Significant dense coalesced staining, corneal abrasion or foreign body tracks.), Grade 4 Severe(Severe abrasions greater than 2 mm in diameter, ulcerations, epithelial loss, or full thickness abrasion.). The total was calculated by using the sum across all regions by time point. The range for the total grade for each time point would be 0-20. The total average grade for each lens and time point was evaluated as an average change from baseline level of corneal staining.

Participating in This Clinical Trial

Inclusion Criteria

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Fluency in English and ability to read and understand written English. 3. The subject must be able and willing to adhere to the instructions set forth in this clinical protocol. 4. The subject must be between 18 and 35 years of age. 5. The subject must be an adapted (minimum of 4 week history of daily wear prior to the baseline study visit) soft contact lens wearer in both eyes. 6. The subject must be East or Southeast Asia descent, e.g. ethnic Chinese, Japanese, Korean, Malay, Vietnamese, Indonesian, Filipino, etc. by self-report. 7. The subject must come in with a current (no more than 12 month old) spectacle or contact lens prescription as indicated. (NB: Emmetropic subjects who wear contact lenses for enhancement purposes only will also require a current contact lens prescription). 8. The subject's vertex corrected spherical equivalent distance refraction must be in the range of PLANO to -6.00 Diopter (D) in each eye. 9. The subject must have best corrected visual acuity on +0.24 logMAR (equivalent to 20/30 (-2)) or better in each eye. 10. The subject must own a wearable pair of spectacles (as indicated by current prescription) and wear them to all visits including the screening visit as required for vision correction. They must be willing to wear their spectacles during the 24 hour washout period leading up to each treatment visit (NB: Emmetropic subjects who do not own spectacles must agree to no lens wear on all visit days including the screening visit). 11. The subject must have normal eye (i.e., no ocular medications or infections of any type). Exclusion Criteria:

1. Are currently pregnant or lactating, determined by self-report (subjects who become pregnant during the study will be discontinued). 2. Have any ocular or systemic allergies or diseases that may interfere with contact lens wear. 3. Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but may not be limited to diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes. 4. Use any topical medication such as eye drops or ointment. 5. Have entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia. 6. Had any previous, or have planned, ocular or intraocular surgery (e.g., cataract surgery, radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK). 7. Have any grade 3.0 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale or any other ocular abnormality that may contraindicate contact lens wear. 8. Have any known hypersensitivity or allergic reaction to contact lenses (as assessed by ocular history). 9. Have any ocular infection. 10. Have any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. 11. Have participated in any contact lens or lens care product clinical trial within 14 days prior to study enrollment. 12. Have any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report. 13. Currently wear their contact lenes on an extended wear basis. 14. Is an employee of the investigational clinic (e.g., Investigator, Coordinator, Technician). 15. Currently wears toric or multifocal contact lenses. If the subject wears soft contact lenses for monovision, they must be willing to wear distance only correction in both eyes for the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Johnson & Johnson Vision Care, Inc.
• Provider of Information About this Clinical Study
  • Sponsor